{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:21:02Z","timestamp":1790252462489,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.14283\/jpad.2022.48","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T05:16:56Z","timestamp":1651123016000},"page":"393-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report"],"prefix":"10.1016","volume":"9","author":[{"given":"Julien","family":"Delrieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Touchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7618","key":"10.14283\/jpad.2022.48_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.14283\/jpad.2022.48_bib2","unstructured":"Budd Haeberlein S, von Hehn C, Tian Y, et al. EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer's Disease. In: 12th Clinical Trials on Alzheimer's Disease. San Diego, 2019."},{"key":"10.14283\/jpad.2022.48_bib3","unstructured":"U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. Aducanumab. Reference ID 4822820 2021."},{"key":"10.14283\/jpad.2022.48_bib4","unstructured":"U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs \u2014 Aducanumab. Reference ID 4807032. 2021."},{"issue":"4","key":"10.14283\/jpad.2022.48_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.14283\/jpad.2021.46","article-title":"Editorial: How Will Aducanumab Approval Impact AD Research?","volume":"8","author":"Weiner","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2022.48_bib6","doi-asserted-by":"crossref","first-page":"n3127","DOI":"10.1136\/bmj.n3127","article-title":"Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"issue":"16","key":"10.14283\/jpad.2022.48_bib7","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2021.15286","article-title":"Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment","volume":"326","author":"Anderson","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"10.14283\/jpad.2022.48_bib8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s12603-021-1657-8","article-title":"Editorial: The Geriatrician, the Primary Care Physician, Aducanumab and the FDA Decision: From Frustration to New Hope","volume":"25","author":"Vellas","year":"2021","journal-title":"J Nutr Health Aging"},{"issue":"4","key":"10.14283\/jpad.2022.48_bib9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: Appropriate Use Recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"10","key":"10.14283\/jpad.2022.48_bib10","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1111\/jgs.17390","article-title":"\u201cReal world\u201d eligibility for aducanumab","volume":"69","author":"Canevelli","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.14283\/jpad.2022.48_bib11","doi-asserted-by":"crossref","first-page":"e12050","DOI":"10.1002\/trc2.12050","article-title":"Alzheimer's disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"10.14283\/jpad.2022.48_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2022.48_bib13","article-title":"Donanemab in Early Alzheimer's Disease","volume":"13","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14283\/jpad.2022.48_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2022.48_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.14283\/jpad.2020.68","article-title":"Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab","volume":"8","author":"Klein","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2022.48_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2022.48_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","article-title":"Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative","volume":"15","author":"Veitch","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.14283\/jpad.2022.48_bib18","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau Kinetics in Neurons and the Human Central Nervous System","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"issue":"7","key":"10.14283\/jpad.2022.48_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.14283\/jpad.2022.48_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2022.48_bib21","first-page":"S1","article-title":"Symposia \u2014 Oral Communications \u2014 Late Breaking News","volume":"8","year":"2021","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"issue":"1","key":"10.14283\/jpad.2022.48_bib22","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer's disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.14283\/jpad.2022.48_bib23","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease","volume":"68","author":"Avgerinos","year":"2021","journal-title":"Ageing Res Rev"},{"issue":"12","key":"10.14283\/jpad.2022.48_bib24","doi-asserted-by":"crossref","first-page":"e2028634","DOI":"10.1001\/jamanetworkopen.2020.28634","article-title":"Assessment of Plasma Amyloid-\u03b242\/40 and Cognitive Decline Among Community-Dwelling Older Adults","volume":"3","author":"Giudici","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.14283\/jpad.2022.48_bib25","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","volume":"12","author":"Cullen","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.14283\/jpad.2022.48_bib26","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat Med"},{"key":"10.14283\/jpad.2022.48_bib27","article-title":"Validation of Plasma Amyloid-\u03b2 42\/40 for Detecting Alzheimer Disease Amyloid Plaques","author":"Li","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.14283\/jpad.2022.48_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14283\/jpad.2021.70","article-title":"Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention","volume":"9","author":"Udeh-Momoh","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"10.14283\/jpad.2022.48_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat Med"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724002978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:11:29Z","timestamp":1737339089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724002978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2274580724002978"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2022.48","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2022.48","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}